Brought to you by 
Merck to sell Daiichi's Lixiana in Europe
22 Mar 2016
Executive Summary
Daiichi Sankyo Europe GMBH (the European marketing arm of Daiichi Sankyo Co.) chose Merck & Co. Inc. to sell its once-daily anti-coagulant Lixiana (edoxaban) in 13 European countries, where Daiichi does not have a market presence.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck to sell Daiichi's Lixiana in Europe
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice